COMMUNIQUÉS West-GlobeNewswire

-
Konica Minolta Healthcare and Apollo Enterprise Imaging Partner to Provide Enterprise-Wide Clinical Workflows and Image-Enabled EMR
26/06/2024 -
Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors
26/06/2024 -
ORYZON Announces Presentation of Final Data From PORTICO, Vafidemstat’s Global Phase IIb Trial in Borderline Personality Disorder, at the 37th ECNP Annual Conference
26/06/2024 -
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
25/06/2024 -
Fennec Announces Results of Annual Meeting
25/06/2024 -
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
25/06/2024 -
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
25/06/2024 -
PetVivo Sets Fiscal Fourth Quarter 2024 Conference Call for Friday, June 28 at 5:00 p.m. ET
25/06/2024 -
TeamHealth Named Among Newsweek’s America’s Greatest Workplaces 2024
25/06/2024 -
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
25/06/2024 -
Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference
25/06/2024 -
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
25/06/2024 -
Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
25/06/2024 -
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion
25/06/2024 -
SAFE - Finalisation des plans de redressement - Reports de l’Assemblée Générale annuelle 2024 et de la publication du rapport financier annuel 2023
25/06/2024 -
Press Release: Availability of the Q2 2024 Aide-mémoire
25/06/2024 -
Communiqué de presse : Mise en ligne du document « Aide-mémoire Q2 2024 »
25/06/2024 -
HFMA Announces Marc Scher as National Chair
25/06/2024 -
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024
25/06/2024
Pages